A four-week trial at the University of Missouri found improved cerebral blood flow from a transplant drug in healthy 45–65-year-olds who carry the APOE4 Alzheimer’s-risk gene — with larger effects in women.
A short, low-dose course of rapamycin increased brain blood flow only in participants who carry the APOE4 gene variant.
Women with APOE4 experienced the greatest improvement in cerebral blood flow.
Results appear in the Journal of Cerebral Blood Flow & Metabolism and were led by University of Missouri researcher Ai-Ling Lin.
# What the study did Researchers at the University of Missouri tested whether a drug already used clinically for other purposes could change brain blood flow in people at higher genetic risk for Alzheimer's disease. The study focused on people who carry the APOE4 gene variant, which is associated with elevated Alzheimer's risk and reduced cerebral blood flow years before symptoms appear.
# Who took part Participants were healthy adults between the ages of 45 and 65 who did not have symptoms of Alzheimer's disease. The sample included people both with and without the APOE4 gene variant so the researchers could compare responses by genetic risk.
# What drug was used and why
# Protocol and main result Participants took a low dose of rapamycin once daily for four weeks. After treatment, only those who carried the APOE4 variant showed improved blood flow in regions of the brain that are relevant to Alzheimer's risk. People without APOE4 did not show the same increase in cerebral blood flow.
# Sex difference reported The researchers report that females with APOE4 experienced the largest improvements in brain blood flow. The study notes this is relevant because nearly two-thirds of people with Alzheimer's are women.
Ai-Ling Lin, a professor in the University of Missouri School of Medicine, framed the findings as an attempt to slow aging in the brain for people at higher genetic risk. She said, "If we can slow down aging in the brain for those people most at risk, maybe we can reduce the risk of them developing Alzheimer's disease."
# Publication and context
# What this does and does not show The trial shows a short course of low-dose rapamycin can increase cerebral blood flow in APOE4 carriers who are middle-aged and symptom-free. It does not show that rapamycin prevents Alzheimer's disease or preserves cognition over the long term. The study establishes a physiological change — improved blood flow — that could be relevant to future prevention research.
# Practical implications For clinicians and patients, this trial suggests a precision-medicine approach: a drug effect that appears specific to a genetically defined subgroup (APOE4 carriers). The sex-specific signal points to the need for subgroup analyses in future trials. Any clinical use of rapamycin for Alzheimer's prevention would require larger, longer trials that measure cognition and safety outcomes over time.
# Next steps suggested by the study
# Bottom line A short, low-dose rapamycin regimen increased brain blood flow in healthy middle-aged adults who carry APOE4, with the strongest gains in women. The finding is an early, targeted physiological result that supports further research on whether this approach can reduce Alzheimer's risk.
Newer blood thinners may do more than prevent strokes in people with Alzheimer’s disease and atrial fibrillation. Researchers found that patients taking NOACs experienced a slower decline in cognitive function than those using warfarin or no blood thinners. The effect was modest each year but could add up over time.
Older adults at risk of dementia improved their memory and thinking after following lifestyle programs combining exercise, healthy eating, cognitive training, and social engagement. Those who received regular coaching and structured support improved substantially more than participants given general health advice.
Healthy middle-aged people deemed to be at higher risk of developing condition among those eligible to participate People without memory loss will be offered an experimental Alzheimer’s drug that could stop the development of the condition before dementia symptoms emerge. Healthy middle-aged people deemed to have a hig
In a small first-of-its-kind human study, high-dose creatine supplements increased brain creatine levels by 11 percent. Researchers say the findings present a greater opportunity.
High-dose vitamin D may improve cognition among those at risk of dementia, according to new research.
Many of the more sophisticated forms of medicine, including gene therapies and immunotherapies, are challenging to deliver to the brain. At the very least there are far fewer practical options for delivery, and it is possible that none of that that exist fit a given desired use case. The blood-brain barrier stands in t
Loading more related stories...
Open the app view to save this story, compare related coverage, and continue from the same source.